Cargando…
The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients
BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. However, its impact on long-term survival remains unclear. We aimed to determine the prognostic value of this discordance in patients with m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996483/ https://www.ncbi.nlm.nih.gov/pubmed/32099389 http://dx.doi.org/10.2147/OTT.S231493 |
_version_ | 1783493522646630400 |
---|---|
author | Yang, Ziyan Li, Nani Li, Xiaolin Lei, Lei Wang, Xiaojia |
author_facet | Yang, Ziyan Li, Nani Li, Xiaolin Lei, Lei Wang, Xiaojia |
author_sort | Yang, Ziyan |
collection | PubMed |
description | BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. However, its impact on long-term survival remains unclear. We aimed to determine the prognostic value of this discordance in patients with metastaticf breast cancer (MBC). METHODS: A total of 270 patients with MBC who were underwent re-biopsy of progressive metastases at Zhejiang Cancer Hospital from January 1, 2012 to December 31, 2015 with patients consent and then review their primary tumors pathological findings. The HR and HER2 status in both primary and progressive metastatic lesions was determined by immunohistochemistry and/or fluorescence in situ hybridization. The discordance rates were correlated with the clinicopathologic characteristics, metastatic lesions, salvage treatment, and survival analysis in this population. RESULTS: A total of 142 (52.6%) MBC patients were diagnosed with discordant HR and HER2 status. Alterations in estrogen receptor (ER), progesterone receptor (PR), and HER2 status were observed in 20.70%, 37.78%, and 11.48% cases, respectively. Chemotherapy (P=0.0192) and endocrine therapy (P=0.048) significantly affected the conversion of HR status. Endocrine therapy was positively correlated with PR discordance (P=0.002), while ER discordance was associated with adjuvant chemotherapy (P=0.031). Survival analysis showed that ER status alterations between primary and metastatic lesions were associated with overall survival (P=0.002). The clinical prognosis was significantly worse with HR losses than with persistent HR positivity (P=0.023). In Cox multivariate analysis, the loss of HR expression and conversion to triple negative were independent prognostic indicators. CONCLUSION: Discordance in HR status between primary and metastatic lesions may impact the prognosis of MBC, and HR conversion has independent prognostic value. |
format | Online Article Text |
id | pubmed-6996483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69964832020-02-25 The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients Yang, Ziyan Li, Nani Li, Xiaolin Lei, Lei Wang, Xiaojia Onco Targets Ther Original Research BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor (HER2) discordance between primary and metastatic breast cancer lesions is common. However, its impact on long-term survival remains unclear. We aimed to determine the prognostic value of this discordance in patients with metastaticf breast cancer (MBC). METHODS: A total of 270 patients with MBC who were underwent re-biopsy of progressive metastases at Zhejiang Cancer Hospital from January 1, 2012 to December 31, 2015 with patients consent and then review their primary tumors pathological findings. The HR and HER2 status in both primary and progressive metastatic lesions was determined by immunohistochemistry and/or fluorescence in situ hybridization. The discordance rates were correlated with the clinicopathologic characteristics, metastatic lesions, salvage treatment, and survival analysis in this population. RESULTS: A total of 142 (52.6%) MBC patients were diagnosed with discordant HR and HER2 status. Alterations in estrogen receptor (ER), progesterone receptor (PR), and HER2 status were observed in 20.70%, 37.78%, and 11.48% cases, respectively. Chemotherapy (P=0.0192) and endocrine therapy (P=0.048) significantly affected the conversion of HR status. Endocrine therapy was positively correlated with PR discordance (P=0.002), while ER discordance was associated with adjuvant chemotherapy (P=0.031). Survival analysis showed that ER status alterations between primary and metastatic lesions were associated with overall survival (P=0.002). The clinical prognosis was significantly worse with HR losses than with persistent HR positivity (P=0.023). In Cox multivariate analysis, the loss of HR expression and conversion to triple negative were independent prognostic indicators. CONCLUSION: Discordance in HR status between primary and metastatic lesions may impact the prognosis of MBC, and HR conversion has independent prognostic value. Dove 2020-01-28 /pmc/articles/PMC6996483/ /pubmed/32099389 http://dx.doi.org/10.2147/OTT.S231493 Text en © 2020 Yang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Yang, Ziyan Li, Nani Li, Xiaolin Lei, Lei Wang, Xiaojia The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
title | The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
title_full | The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
title_fullStr | The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
title_full_unstemmed | The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
title_short | The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
title_sort | prognostic impact of hormonal receptor and her-2 expression discordance in metastatic breast cancer patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996483/ https://www.ncbi.nlm.nih.gov/pubmed/32099389 http://dx.doi.org/10.2147/OTT.S231493 |
work_keys_str_mv | AT yangziyan theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT linani theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT lixiaolin theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT leilei theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT wangxiaojia theprognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT yangziyan prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT linani prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT lixiaolin prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT leilei prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients AT wangxiaojia prognosticimpactofhormonalreceptorandher2expressiondiscordanceinmetastaticbreastcancerpatients |